- Home
- CHRS vs FSFG Comparison
CHRS vs FSFG Comparison
Compare CHRS & FSFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FSFG
- Stock Information
- Founded
- CHRS 2010
- FSFG 2008
- Country
- CHRS United States
- FSFG United States
- Employees
- CHRS N/A
- FSFG N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FSFG Savings Institutions
- Sector
- CHRS Health Care
- FSFG Finance
- Exchange
- CHRS Nasdaq
- FSFG Nasdaq
- Market Cap
- CHRS 191.3M
- FSFG N/A
- IPO Year
- CHRS 2014
- FSFG 2008
- Fundamental
- Price
- CHRS $1.39
- FSFG $25.18
- Analyst Decision
- CHRS Strong Buy
- FSFG Buy
- Analyst Count
- CHRS 4
- FSFG 1
- Target Price
- CHRS $5.38
- FSFG $31.00
- AVG Volume (30 Days)
- CHRS 2.0M
- FSFG 13.8K
- Earning Date
- CHRS 03-12-2025
- FSFG 01-28-2025
- Dividend Yield
- CHRS N/A
- FSFG 2.34%
- EPS Growth
- CHRS N/A
- FSFG 66.39
- EPS
- CHRS N/A
- FSFG 1.98
- Revenue
- CHRS $304,340,000.00
- FSFG $68,091,000.00
- Revenue This Year
- CHRS $2.47
- FSFG N/A
- Revenue Next Year
- CHRS N/A
- FSFG $2.77
- P/E Ratio
- CHRS N/A
- FSFG $12.95
- Revenue Growth
- CHRS 44.19
- FSFG N/A
- 52 Week Low
- CHRS $0.66
- FSFG $14.55
- 52 Week High
- CHRS $2.97
- FSFG $30.94
- Technical
- Relative Strength Index (RSI)
- CHRS 45.86
- FSFG 41.19
- Support Level
- CHRS $1.38
- FSFG $24.20
- Resistance Level
- CHRS $1.60
- FSFG $27.17
- Average True Range (ATR)
- CHRS 0.13
- FSFG 0.79
- MACD
- CHRS -0.03
- FSFG -0.02
- Stochastic Oscillator
- CHRS 9.52
- FSFG 33.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.